Genekam Biotechnology AG services

Genekam has developed human exosome isolation kit from different sources like cell cultures, serum, plasma, saliva, tumor samples etc. Exosomes are extra cellular message transmission vehicles, which carry information between the different cells and it seems that they play an important role during the physiological and pathological processes. Isolation of exosomes can be achieved with different methods e.g. ultracentrifugation, density gradient method, filtration, chromatography, magnetic beads etc. Magnetic beads are one of simplest, less expensive and easiest method to do their isolation. Exosomes have different markers, which are being used to isolate them. After the isolation, one can detect them with different methods like microscopic, immunological assays as well as molecular methods. Genekam biotechnology AG has different methods for isolation for them along with their detection methods. Isolation methods are based on magnetic beads.

Genekam Biotechnology AG has developed a number of solutions and molecules, which can be used to inhibit the Ebola infections in order to create new therapies. These molecules can be sourced from us and laboratories around the world can conduct the research studies e.g. preclinical and clinical to demostrate that these molecules can inhibit the Ebola viruses. Not only this, we are trying to develop more molecules to inhibit the Middle east Respiratory syndrome viruses infections (SARS virus), dengue viruses, Influenza viruses as well as animal viruses like Foot and mouth disease etc.

There are many laboratories developing CAR T-cell therapies. Genekam has a number of kits to develop CAR T-Cell therapy e.g. isolate large number of T cells (CD4 / CD8) from blood or other source. This isolation kit will generate larger number of needed T cells against number of cells generated through density gradient methods (also called Ficolle), Magnetic beads based Kits are for separation of wanted T cells from other unwanted cells. After that they can be stimulated or undergo the cloning with specific vectors carrying specific sequences. Genekam has developed a kit, which can remove the unwanted erythrocytes, which may be disturbing factors during the development. This can accelerate the development of CAR T-cells therapies against any possible target in field oncology, virology or transplantation medicine. These kits help to make therapies economically.